Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.

Muszbek N, Proudfoot C, Fournier M, Chen CI, Kuznik A, Kiss Z, Gal P, Michaud K.

Adv Ther. 2019 Jun;36(6):1337-1357. doi: 10.1007/s12325-019-00946-1. Epub 2019 Apr 19.

PMID:
31004324
2.

Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.

Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, Van Hoogstraten H, Mangan E, Carita P, Huynh TM.

RMD Open. 2019 Feb 18;5(1):e000798. doi: 10.1136/rmdopen-2018-000798. eCollection 2019.

3.

Effects of Sarilumab on Patient-Reported Impact of Rheumatoid Arthritis Using the Rheumatoid Arthritis Impact of Disease Scale.

Gossec L, Strand V, Proudfoot C, Chen CI, Guillonneau S, Kimura T, van Hoogstraten H, Mangan E, Reaney M.

J Rheumatol. 2019 Mar 15. pii: jrheum.180904. doi: 10.3899/jrheum.180904. [Epub ahead of print]

4.

Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs.

Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, van Hoogstraten H, Mangan E, Carita P, Huynh TM.

Adv Ther. 2019 Apr;36(4):817-827. doi: 10.1007/s12325-019-00912-x. Epub 2019 Mar 12.

PMID:
30864105
5.

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient.

Fournier M, Chen CI, Kuznik A, Proudfoot C, Mallya UG, Michaud K.

Clinicoecon Outcomes Res. 2019 Feb 5;11:117-128. doi: 10.2147/CEOR.S183076. eCollection 2019.

6.

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies.

Ferrufino CP, Munakata J, Wei W, Proudfoot C, Kuznik A, Boklage SH, Chen CI.

Clinicoecon Outcomes Res. 2018 Nov 16;10:805-819. doi: 10.2147/CEOR.S163829. eCollection 2018. Erratum in: Clinicoecon Outcomes Res. 2019 Jan 14;11:83-85.

7.

Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.

Bonafede MMK, McMorrow D, Proudfoot C, Shinde S, Kuznik A, Chen CI.

Am Health Drug Benefits. 2018 Jun;11(4):192-202.

8.

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.

Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR.

Arthritis Res Ther. 2018 Jun 19;20(1):129. doi: 10.1186/s13075-018-1614-z.

9.

Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.

Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W.

Adv Ther. 2017 Nov;34(11):2422-2435. doi: 10.1007/s12325-017-0617-5. Epub 2017 Oct 16.

10.

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y, Pacheco-Tena C, Fleischmann R.

RMD Open. 2017 Mar 7;3(1):e000416. doi: 10.1136/rmdopen-2016-000416. eCollection 2017.

11.

Comparison of CRISPR/Cas9 and TALENs on editing an integrated EGFP gene in the genome of HEK293FT cells.

He Z, Proudfoot C, Whitelaw CB, Lillico SG.

Springerplus. 2016 Jun 21;5(1):814. doi: 10.1186/s40064-016-2536-3. eCollection 2016.

12.

Mammalian interspecies substitution of immune modulatory alleles by genome editing.

Lillico SG, Proudfoot C, King TJ, Tan W, Zhang L, Mardjuki R, Paschon DE, Rebar EJ, Urnov FD, Mileham AJ, McLaren DG, Whitelaw CB.

Sci Rep. 2016 Feb 22;6:21645. doi: 10.1038/srep21645.

13.

Genetically engineering milk.

Whitelaw CB, Joshi A, Kumar S, Lillico SG, Proudfoot C.

J Dairy Res. 2016 Feb;83(1):3-11. doi: 10.1017/S0022029916000017. Review.

14.

Gene targeting, genome editing: from Dolly to editors.

Tan W, Proudfoot C, Lillico SG, Whitelaw CB.

Transgenic Res. 2016 Jun;25(3):273-87. doi: 10.1007/s11248-016-9932-x. Epub 2016 Feb 3. Review.

15.

Comparison of surrogate reporter systems for enrichment of cells with mutations induced by genome editors.

He Z, Shi X, Liu M, Sun G, Proudfoot C, Whitelaw CB, Lillico SG, Chen Y.

J Biotechnol. 2016 Mar 10;221:49-54. doi: 10.1016/j.jbiotec.2016.01.009. Epub 2016 Jan 14.

PMID:
26778541
16.

Cardiovascular Event Rates in a High-Risk General Population Cohort of 340,000 Individuals in the United Kingdom.

Ansell D, Khan I, Proudfoot C, Gbenedio T, Joulain F, Pockett RD, Catterick D, Gooch K.

Value Health. 2015 Nov;18(7):A382-3. doi: 10.1016/j.jval.2015.09.821. Epub 2015 Oct 20. No abstract available.

17.

Highly efficient targeted chromosome deletions using CRISPR/Cas9.

He Z, Proudfoot C, Mileham AJ, McLaren DG, Whitelaw CB, Lillico SG.

Biotechnol Bioeng. 2015 May;112(5):1060-4. doi: 10.1002/bit.25490. Epub 2014 Dec 23.

PMID:
25362885
18.

Methodological Evaluation Of The Impact Of Survival Costs In Oncology Modelling.

Taylor M, Filby A, Proudfoot C.

Value Health. 2014 Nov;17(7):A562-3. doi: 10.1016/j.jval.2014.08.1863. Epub 2014 Oct 26. No abstract available.

19.

Genome edited sheep and cattle.

Proudfoot C, Carlson DF, Huddart R, Long CR, Pryor JH, King TJ, Lillico SG, Mileham AJ, McLaren DG, Whitelaw CB, Fahrenkrug SC.

Transgenic Res. 2015 Feb;24(1):147-53. doi: 10.1007/s11248-014-9832-x. Epub 2014 Sep 10.

20.

Generation of functional neurons from feeder-free, keratinocyte-derived equine induced pluripotent stem cells.

Sharma R, Livesey MR, Wyllie DJ, Proudfoot C, Whitelaw CB, Hay DC, Donadeu FX.

Stem Cells Dev. 2014 Jul 1;23(13):1524-34. doi: 10.1089/scd.2013.0565. Epub 2014 Mar 25.

PMID:
24548115
21.

Live pigs produced from genome edited zygotes.

Lillico SG, Proudfoot C, Carlson DF, Stverakova D, Neil C, Blain C, King TJ, Ritchie WA, Tan W, Mileham AJ, McLaren DG, Fahrenkrug SC, Whitelaw CB.

Sci Rep. 2013 Oct 10;3:2847. doi: 10.1038/srep02847.

22.

Efficient TALEN-mediated gene knockout in livestock.

Carlson DF, Tan W, Lillico SG, Stverakova D, Proudfoot C, Christian M, Voytas DF, Long CR, Whitelaw CB, Fahrenkrug SC.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17382-7. doi: 10.1073/pnas.1211446109. Epub 2012 Oct 1.

23.

Impact of a nurse-led clinic for chronic constipation in children.

Ismail N, Ratchford I, Proudfoot C, Gibbs J.

J Child Health Care. 2011 Sep;15(3):221-9. doi: 10.1177/1367493511406568. Epub 2011 Aug 9.

PMID:
21828166
24.

A national audit of pollen immunotherapy for children in the United Kingdom: patient selection and programme safety.

Vance GH, Goldring S, Warner JO, Cox H, Sihra B, Hughes S, Gardner J, North J, Roberts G, Proudfoot CA, Clarke A, Luyt DK, Gillies D, Fox AT.

Clin Exp Allergy. 2011 Sep;41(9):1313-23. doi: 10.1111/j.1365-2222.2011.03803.x. Epub 2011 Jul 15.

PMID:
21762222
25.

Zinc finger recombinases with adaptable DNA sequence specificity.

Proudfoot C, McPherson AL, Kolb AF, Stark WM.

PLoS One. 2011 Apr 29;6(4):e19537. doi: 10.1371/journal.pone.0019537.

26.

A systematic literature review of the efficacy and safety of the Prostar XL device for the closure of large femoral arterial access sites in patients undergoing percutaneous endovascular aortic procedures.

Haulon S, Hassen Khodja R, Proudfoot CW, Samuels E.

Eur J Vasc Endovasc Surg. 2011 Feb;41(2):201-13. doi: 10.1016/j.ejvs.2010.10.015. Epub 2010 Dec 8. Review.

27.

A systematic review of the impact of sedation practice in the ICU on resource use, costs and patient safety.

Jackson DL, Proudfoot CW, Cann KF, Walsh T.

Crit Care. 2010;14(2):R59. doi: 10.1186/cc8956. Epub 2010 Apr 9. Review.

28.

The incidence of sub-optimal sedation in the ICU: a systematic review.

Jackson DL, Proudfoot CW, Cann KF, Walsh TS.

Crit Care. 2009;13(6):R204. doi: 10.1186/cc8212. Epub 2009 Dec 16. Review.

29.

Cold comfort pharm.

Fleetwood-Walker SM, Proudfoot CW, Garry EM, Allchorne A, Vinuela-Fernandez I, Mitchell R.

Trends Pharmacol Sci. 2007 Dec;28(12):621-8. Epub 2007 Nov 9. Review.

30.

Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain.

Proudfoot CJ, Garry EM, Cottrell DF, Rosie R, Anderson H, Robertson DC, Fleetwood-Walker SM, Mitchell R.

Curr Biol. 2006 Aug 22;16(16):1591-605.

31.

Site-specific skin reactions to amethocaine.

Proudfoot C, Gamble C.

Paediatr Nurs. 2006 Jun;18(5):26-8.

PMID:
16784060
32.

Distinct roles for two RAD51-related genes in Trypanosoma brucei antigenic variation.

Proudfoot C, McCulloch R.

Nucleic Acids Res. 2005 Dec 2;33(21):6906-19. Print 2005.

33.

Trypanosoma brucei DMC1 does not act in DNA recombination, repair or antigenic variation in bloodstream stage cells.

Proudfoot C, McCulloch R.

Mol Biochem Parasitol. 2006 Feb;145(2):245-53. Epub 2005 Oct 26.

PMID:
16289356
34.

Two pathways of homologous recombination in Trypanosoma brucei.

Conway C, Proudfoot C, Burton P, Barry JD, McCulloch R.

Mol Microbiol. 2002 Sep;45(6):1687-700.

Supplemental Content

Loading ...
Support Center